{"head":{"slug":"biogen-inc","name":"Biogen Inc","symbol":"BIIB","sector":"Healthcare","overallScore":4.5,"overallClassification":"SELL","displayName":"Biogen Inc"},"scores":[{"classification":"SELL","strategyName":"StockScorer-Score","strategySlug":"stockscorer-score"},{"classification":"SELL","strategyName":"Piotroski F-Score (9-Punkte-Bilanzcheck)","strategySlug":"finanzielle-gesundheit"},{"classification":"SELL","strategyName":"Mohanram G-Score: Wachstums-Qualität","strategySlug":"wachstums-qualitaet-g-score"},{"classification":"HOLD","strategyName":"Unterbewertete Aktien: Mehrfaktor-Check","strategySlug":"unterbewertung-mehrfaktor"},{"classification":"BUY","strategyName":"Altman Z-Score: Bilanz-Stresstest","strategySlug":"bilanz-stresstest-z-score"},{"classification":"BUY","strategyName":"Ertragsqualität: Accrual-Check (Sloan)","strategySlug":"ertragsqualitaet-accrual-check"}],"radar":{"categories":["profitability","growth","valuation","momentum"],"median":[33.3,0,0,0],"values":[33.3,0,100,100]},"peers":[{"classification":"BUY","displayName":"Bristol-Myers Squibb Company","locked":false,"name":"Bristol-Myers Squibb Company","overallScore":7.3,"slug":"bristol-myers-squibb-company","symbol":"BMY"},{"classification":null,"displayName":"Otsuka Holdings Ltd","locked":true,"name":"Otsuka Holdings Ltd","overallScore":null,"slug":"otsuka-holdings-co-ltd","symbol":"4578.T"},{"classification":null,"displayName":"Daiichi Sankyo Co. Ltd.","locked":true,"name":"Daiichi Sankyo Co. Ltd.","overallScore":null,"slug":"daiichi-sankyo-company-limited","symbol":"4568.T"},{"classification":null,"displayName":"Astellas Pharma Inc.","locked":true,"name":"Astellas Pharma Inc.","overallScore":null,"slug":"astellas-pharma-inc","symbol":"4503.T"},{"classification":null,"displayName":"Orion Oyj B","locked":true,"name":"Orion Oyj B","overallScore":null,"slug":"orion-oyj-ornbv-he","symbol":"ORNBV.HE"}],"metrics":{"current_ratio":2.67931569833403,"dividend_growth":null,"dividend_payout_ratio":0,"dividend_streak_years":null,"dividend_yield":0,"dte":0.38057052714604966,"earnings_growth_3y":-24.964882308532278,"equity_ratio":62.014640194296774,"ev_ebit":21.583539911792805,"fcf_margin":20.903920249526024,"fcf_yield":5.484772214762623,"kbv":1.9955821940318128,"kgv":28.168590424071954,"one_yr":48.840698269901694,"peg":-2.9522517769597165,"revenue_growth":1.3921185626143195,"roc_greenblatt":20.988206360740037,"roe":7.084423338153455},"quote":{"currency":"USD","exchange":"NASDAQ","marketCap":37390796184.39099,"marketCapEur":33554500367.873627,"price":248.35,"priceAsOf":"2026-11-06"},"sectorMedians":{"current_ratio":1.5836203666775437,"dividend_growth":5.623306233062331,"dividend_payout_ratio":35.91314413087717,"dividend_streak_years":10,"dividend_yield":1.3483331598261532,"dte":0.4838372886800787,"earnings_growth_3y":5.440658922332009,"equity_ratio":48.4008953898299,"ev_ebit":21.726364951966808,"fcf_margin":14.117834756719867,"fcf_yield":3.629326385869834,"kbv":4.751254808572999,"kgv":29.969658033759437,"one_yr":8.663206112670974,"peg":1.5047753142982023,"revenue_growth":8.039862019201006,"roc_greenblatt":32.54750002450021,"roe":11.52412853150564},"sectorPercentiles":{"current_ratio":76,"dividend_growth":null,"dividend_payout_ratio":10,"dividend_streak_years":null,"dividend_yield":9,"dte":45,"earnings_growth_3y":8,"equity_ratio":69,"ev_ebit":48,"fcf_margin":72,"fcf_yield":77,"kbv":17,"kgv":43,"one_yr":89,"peg":null,"revenue_growth":17,"roc_greenblatt":28,"roe":28},"sectorProfile":{"radar":{"categories":["profitability","growth","valuation","momentum","quality","risk"],"median":[50,50,50,50,50,50],"values":[49.7,11.8,59.7,75.5,23.3,54.2]},"sectorRank":45.7,"strongest":"momentum","weakest":"growth"},"flagshipRules":[{"id":"ss-31","knockout":false,"points":2,"status":"met"},{"id":"ss-32","knockout":false,"points":2,"status":"unmet"},{"id":"ss-33","knockout":false,"points":1,"status":"unmet"},{"id":"ss-34","knockout":false,"points":2,"status":"met"},{"id":"ss-27","knockout":false,"points":2,"status":"unmet"},{"id":"ss-28","knockout":false,"points":1,"status":"unmet"},{"id":"ss-29","knockout":false,"points":1,"status":"met"},{"id":"ss-30","knockout":false,"points":0,"status":"unmet"}],"strategyLockedNames":[{"strategyName":"Wachstums-Momentum (CAN-SLIM-Prinzip)","strategySlug":"wachstums-momentum"},{"strategyName":"Trending Value: Value + Momentum","strategySlug":"value-momentum"},{"strategyName":"Defensiv: Low Volatility","strategySlug":"defensiv-low-volatility"},{"strategyName":"Burggraben-Qualität","strategySlug":"burggraben-qualitaet"},{"strategyName":"Magic Formula: Value + Qualität","strategySlug":"qualitaet-value"},{"strategyName":"Acquirer's Multiple: EV/EBIT Deep Value","strategySlug":"ev-ebit-deep-value"},{"strategyName":"Dividenden-Aristokraten & Kontinuität","strategySlug":"dividenden-kontinuitaet"},{"strategyName":"Dividenden-Qualität: 4 Faktoren","strategySlug":"dividenden-qualitaet"},{"strategyName":"GARP Ausgewogen","strategySlug":"garp-ausgewogen"},{"strategyName":"High-Growth / Rule of 40","strategySlug":"high-growth-rule-of-40"},{"strategyName":"Levermann-Strategie (13 Kriterien)","strategySlug":"13-kriterien-punktesystem"},{"strategyName":"PEG-Strategie nach Peter Lynch","strategySlug":"peg-strategie"}],"company":{"description":"Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.","industry":"Drug Manufacturers - General","ipoDate":"1991-09-16"},"sectorBreakdown":{"growth":{"metrics":[{"counts":true,"field":"revenue_growth","lowerIsBetter":false,"rank":17,"sectorMedian":8.039862019201006,"value":1.3921185626143195},{"counts":true,"field":"earnings_growth_3y","lowerIsBetter":false,"rank":7.5,"sectorMedian":5.440658922332009,"value":-24.964882308532278},{"counts":true,"field":"earnings_growth_5y","lowerIsBetter":false,"rank":4,"sectorMedian":7.003389122494063,"value":-18.68668680643686},{"counts":true,"field":"sus_growth","lowerIsBetter":false,"rank":18.8,"sectorMedian":3.6635701466492088,"value":1.5676920881495526}],"value":11.8},"momentum":{"metrics":[{"counts":true,"field":"one_yr","lowerIsBetter":false,"rank":88.8,"sectorMedian":8.663206112670974,"value":48.840698269901694},{"counts":true,"field":"six_m","lowerIsBetter":false,"rank":62.9,"sectorMedian":24.27032259851255,"value":28.862879158880784},{"counts":true,"field":"three_m","lowerIsBetter":false,"rank":78.1,"sectorMedian":15.416211475410979,"value":24.564863072113482},{"counts":true,"field":"pct_from_52w_high","lowerIsBetter":false,"rank":72.3,"sectorMedian":-7.345407316545205,"value":-2.4011632476617195}],"value":75.5},"profitability":{"metrics":[{"counts":true,"field":"roe","lowerIsBetter":false,"rank":27.7,"sectorMedian":11.52412853150564,"value":7.084423338153455},{"counts":true,"field":"roc_greenblatt","lowerIsBetter":false,"rank":27.9,"sectorMedian":32.54750002450021,"value":20.988206360740037},{"counts":true,"field":"ebit_margin","lowerIsBetter":false,"rank":54.8,"sectorMedian":18.305086092796074,"value":19.137463559823047},{"counts":true,"field":"fcf_margin","lowerIsBetter":false,"rank":72.4,"sectorMedian":14.117834756719867,"value":20.903920249526024},{"counts":true,"field":"gross_margin","lowerIsBetter":false,"rank":65.8,"sectorMedian":60.99422024571629,"value":70.47071534870446}],"value":49.7},"quality":{"metrics":[{"counts":true,"field":"sloan_ratio","lowerIsBetter":true,"rank":39.9,"sectorMedian":0.2985136689791994,"value":1.5999255507159655},{"counts":true,"field":"share_change","lowerIsBetter":true,"rank":19.8,"sectorMedian":-0.002392665312306813,"value":0.5483207676490748},{"counts":true,"field":"dividend_streak_years","lowerIsBetter":false,"rank":12.9,"sectorMedian":10,"value":null},{"counts":true,"field":"reaction_rel","lowerIsBetter":false,"rank":20.5,"sectorMedian":0.05056951189927883,"value":-3.6657203220403445}],"value":23.3},"risk":{"metrics":[{"counts":true,"field":"equity_ratio","lowerIsBetter":false,"rank":69.4,"sectorMedian":48.4008953898299,"value":62.014640194296774},{"counts":true,"field":"debt_to_ebitda","lowerIsBetter":true,"rank":50.8,"sectorMedian":1.1117596945697787,"value":1.0635632066822858},{"counts":true,"field":"dte","lowerIsBetter":true,"rank":55.2,"sectorMedian":0.4838372886800787,"value":0.38057052714604966},{"counts":true,"field":"volatility_1y","lowerIsBetter":true,"rank":41.4,"sectorMedian":31.42353880746313,"value":34.28456373566406}],"value":54.2},"valuation":{"metrics":[{"counts":true,"field":"earnings_yield","lowerIsBetter":false,"rank":61.5,"sectorMedian":2.8966594312400864,"value":3.550053392609354},{"counts":true,"field":"fcf_yield","lowerIsBetter":false,"rank":76.6,"sectorMedian":3.629326385869834,"value":5.484772214762623},{"counts":true,"field":"ev_to_sales","lowerIsBetter":true,"rank":48.2,"sectorMedian":4.026437265234489,"value":4.130542085539211},{"counts":true,"field":"ev_ebit","lowerIsBetter":true,"rank":52.3,"sectorMedian":21.726364951966808,"value":21.583539911792805}],"value":59.7}},"expectation":{"inputs":{"basis":"fcf","capex":null,"capexDepressed":false,"fcf":2050800000,"fcfBasis":"fy","fcfNormalized":null,"fcfWindowEnd":null,"fcfYear":2025,"kbv":1.9955821940318128,"marketCap":37390796184.39099,"marks":{"fiveYear":-10.77,"tenYear":-7.27}},"standard":{"basis":"fcf","case":"aboveMarks","discountRate":9,"noGrowthValue":22786666666.666668,"value":6.965865928441417,"years":10},"standardNormalized":null},"quarterChanges":{"case":"mostlyWorse","changes":[{"change":13.17,"current":2968700000,"direction":"better","metric":"fcf","previous":2623200000,"signChange":false,"unit":"percent"},{"change":-2.06,"current":67.71,"direction":"worse","metric":"grossMargin","previous":69.77,"signChange":false,"unit":"pp"},{"change":-2.86,"current":12.79,"direction":"worse","metric":"ebitMargin","previous":15.65,"signChange":false,"unit":"pp"},{"change":3.23,"current":29.84,"direction":"better","metric":"fcfMargin","previous":26.61,"signChange":false,"unit":"pp"},{"change":122.39,"current":7070100000,"direction":"worse","metric":"netDebt","previous":3179200000,"signChange":false,"unit":"percent"},{"change":-2.93,"current":4.43,"direction":"worse","metric":"roe","previous":7.36,"signChange":false,"unit":"pp"}],"current":{"quarter":2,"year":2026},"previous":{"quarter":1,"year":2026},"unchanged":["revenue","sharesOutstanding"]},"evidence":{"anomalies":[{"key":"earnings_decline","value":-20.76},{"key":"ebit_margin_falling","value":-11.68},{"key":"volatile_earnings","value":4}],"contra":["expectationAboveHistory","earnings_decline","ebit_margin_falling","volatile_earnings"],"moat":[{"holds":false,"key":"stableGrossMargin","median":83.59,"spread":17.01,"years":10},{"first":80.79,"holds":false,"key":"risingGrossMargin","last":70.47,"years":5},{"holds":false,"key":"highReturnOnCapital","min":7.2,"years":10},{"holds":true,"key":"lowCapitalIntensity","median":3.65,"years":10},{"holds":false,"key":"steadyFcfMargin","min":11.25,"spread":34.4,"years":10}],"phase":{"ebitMargin":19.1,"financingCf":-301900000,"investingCf":-1371100000,"key":"steady","operatingCf":2204600000,"payoutShare":0,"revenueCagr3y":-1.2,"revenueGrowthYoy":null},"pro":["lowCapitalIntensity"]},"valuationBand":{"anchor":{"quarter":2,"year":2026},"high":20.4,"low":10.1,"median":12.5,"metric":"priceToOcf","multiple":12.8,"position":"within","priceAsOf":"2026-11-06","quarters":20}}